参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Cervical Cancer Version 3.2019 — December 17, 2018.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed., 2017).
3.Thomeer MG, Gerestein C, Spronk S, et al.Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis.Eur Radiol 2013, 23: 2005-2018.
4.Park DA, Yun JE, Kim SW, et al.Surgical and clinical safety and effectiveness of robot-assisted laparoscopic hysterectomy compared to conventional laparoscopy and laparotomy for cervical cancer: A systematic review and meta-analysis.Eur J Surg Oncol 2017, 43: 994-1002.
5.Parra-Herran C, Taljaard M, Djordjevic B, et al.Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists.Mod Pathol 2016, 29: 879-892.
6.Gee MS, Atri M, Bandos AI, et al.Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial.Radiology 2018, 287: 176-184.
7.Salani R, Khanna N, Frimer M, et al.An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO)recommendations.Gynecol Oncol 2017, 146: 3-10.
8.Roma AA, Mistretta TA, Diaz De Vivar A, et al.New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.Gynecol Oncol 2016, 141: 36-42.
9.Frumovitz M, Plante M, Lee PS, et al.The FILM Trial: A randomized phase III multicenter study assessing near infrared fluorescence in the identification of sentinel lymph nodes (SLN)［Abstract］.Gynecologic Oncology 2018, 149: 7.
10.Tewari KS, Sill MW, Penson RT, et al.Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, openlabel, phase 3 trial (Gynecologic Oncology Group 240).Lancet 2017, 390: 1654-1663.
11.Rutgers JK, Roma AA, Park KJ, et al.Pattern classification of endocervical adenocarcinoma: reproducibility and review of criteria.Mod Pathol 2016, 29: 1083-1094.(https://www.daowen.com)
12.Ramirez PT, Frumovitz M, Pareja R, et al.Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.N Engl J Med 2018.
13.Rosen VM, Guerra I, McCormack M, et al.Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.Int J Gynecol Cancer 2017, 27: 1237-1246.
14.Bentivegna E, Gouy S, Maulard A, et al.Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.Lancet Oncol 2016, 17: e240-253.
15.Melamed A, Margul DJ, Chen L, et al.Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.N Engl J Med 2018.
16.Le DT, Durham JN, Smith KN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science 2017, 357: 409-413.
17.Ruscito I, Gasparri ML, Braicu EI, et al.Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis.Ann Surg Oncol 2016, 23: 3749-3756.
18.Margul DJ, Yang J, Seagle BL, et al.Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer.Journal of Clinical Oncology 2018, 36: 5502-5502.
19.Frenel JS, Le Tourneau C, O'Neil B, et al.Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.J Clin Oncol 2017, 35: 4035-4041.
20.Sert BM, Boggess JF, Ahmad S, et al.Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer.Eur J Surg Oncol 2016, 42: 513-522.
21.Atri M, Zhang Z, Dehdashti F, et al.Utility of PETCT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.Gynecol Oncol 2016, 142: 413-419.